Review decision - August 2010

Review of NICE Technology Appraisal Guidance No 91; Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for the treatment of advanced ovarian cancer (for relapsed disease only)

The Institute proposed that the review of the original guidance be deferred until November 2012, to allow on-going research that would potentially inform a review to become available.

During consultation it was highlighted to us that the proposal might not be the best way to proceed with the review. A summary of the responses from this consultation are attached as appendix A. After consideration of all these comments, the Institute's Guidance Executive has decided to recommend that a review of the original guidance should be planned into the NICE work programme, to coincide with the presentation of full results of the CALYPSO trial (NCT00189553). Trabectedin should also be included within this review along with gemcitabine. The inclusion of gemcitabine would be subject to approval from the Department of Health. 

 

August 2010

This page was last updated: 01 September 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.